Restricting ‘Pay-for-Delay’ Agreements
This post discusses recent fines imposed on pharmaceutical companies for pay-for-delay agreements and examines their impact on market competition and drug pricing. It analyses regulatory measures and the…
drug pricing
2 articles
Gilead, IPA, Natco & The Bells of Harmony
The post examines the collaboration between Gilead, IPA, and Natco Pharma regarding the sofosbuvir patent in India. It analyses how voluntary licensing and innovative policies are improving access…